Navigation Links
Mayo Clinic: Drug induces morphologic, molecular and clinical remissions in myelofibrosis
Date:12/5/2013

ROCHESTER, Minn. -- Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

"These are early results but they are promising, says the study's lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. "Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease."

Myelofibrosis is a chronic myeloid cancer in which bone marrow cells that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their blood stem cells, including JAK2, MPL, CALR, ASXL1 and spliceosome pathway mutations.

"Typically, myelofibrosis is characterized by marrow scarring and although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow," Dr. Tefferi says. "Some patients in our trial have reverted back to normal bone marrow."

Imetelstat works by inhibiting telomerase activity in tumor cells which leads to cell death.

Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for a minimum of six months. Among the 22, five patients achieved complete or partial remissions, including reversal of bone marrow fibrosis in four of the five patients. Two of the five patients with complete or partial remission have also experienced complete molecular remissions. The overall response rate was 41 percent.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1

Related medicine news :

1. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
2. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
3. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
4. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
5. Mayo Clinic: Common blood pressure drug linked to severe GI problems
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
8. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
9. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
10. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
11. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize critical ... leave patients with dental emergencies at risk of losing a tooth or their smiles. ... , Common dental emergencies include:, , Avulsed or knocked-out ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ... Care Association™ (ALCA) to conduct a survey that takes a closer look at cases ... illustrates the prevalence and causes of TBI among the aging population, and identifies the ...
(Date:2/10/2016)... ... 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused ... full year ended December 31, 2015 on Monday, February 29, 2016 after the market ... community following the release at 4:30 PM ET. Investors interested in participating by phone ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & ... PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless steel with ... of biological samples while operating at ultra-high pressures of 20,000 psi. The higher ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... SUNNYVALE, Calif. , Feb. 10, 2016 /PRNewswire/ ... Warren Kocmond , formerly Executive Vice President ... the position of President and Chief Operating Officer.  ... been expanded, and now include Global Commercial Operations ... and Customer Service.  Mr. Kocmond will continue to ...
(Date:2/10/2016)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... full year ended December 31, 2015. ... year for Vanda with the continued growth of HETLIOZ ... HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s ... U.S. product portfolio builds on this success and underscores ...
(Date:2/10/2016)... LEXINGTON, Massachusetts , February 10, 2016 --> ... Japan .  --> Japan .  ... Japan .  With submission, Shire continues to ... --> With submission, Shire continues to ... With submission, Shire continues to strengthen ...
Breaking Medicine Technology: